Grunenthal, Horizon sign commercialization contract for Duexis in Latin America

Duexis is a proprietary single-tablet combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine.

The product is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, in the US.

Horizon Pharma chairman, president and chief executive officer Timothy Walbert said the partnership with Grunenthal in Latin America is the company’s first out-license of Duexis outside the US.

"This agreement, in addition to our recent U.S. co-promotion with Mallinckrodt, the pharmaceutical business of Covidien, is a continuation of our strategy to expand the availability of DUEXIS to patients worldwide," Walbert added.